Neurotrack Technologies, Inc.

Neurotrack Technologies develops FDA-registered digital cognitive screening tools for early detection of mild cognitive impairment (MCI), Alzheimer's disease, and related dementias. The platform delivers standardized, cloud-based cognitive assessments in as little as 3 minutes, enabling rapid baseline measurement and DSM-5-aligned diagnostic scoring. The solution integrates with all major EHR systems, deploys on any device, and supports remote and in-clinic administration. Neurotrack serves healthcare providers, health plans, home health agencies, and primary care settings, with over 15,000 clinicians and major health systems (Providence, Sutter Health, Stanford Medicine) as customers. The company emphasizes operational efficiency—reducing administration time by 10+ minutes compared to traditional tests like Mini-Cog, MMSE, and MoCA—while improving clinical outcomes through actionable care plans and population health management for value-based reimbursement models. Clinically validated by 375+ peer-reviewed publications and 25 core studies, with funding from the National Institute on Aging and the Gates Foundation. SOC 2- and HIPAA-compliant. Founded in 2012 with a singular focus on closing the dementia detection gap.